|Primary analysis complete
|Study Start Date:
|Study Made Public:
A multicenter double-blind randomized placebo-controlled Phase IIB test-of-concept study to evaluate the safety and efficacy of a 3-dose regimen of the Clade B-based Merck Adenovirus serotype 5 HIV-1 gag/pol/nef vaccine in HIV-1-uninfected adults in South Africa
HVTN 503 (Phambili) is a Phase IIb clinical trial to evaluate the safety and immunogenicity of MRKAd5 HIV-1 gag/pol/nef (Ad5).
Sign in to see full information about this study and to download study data.
ProductsProduct info coming soon!
No integrated data is available for this study.
No non-integrated data is available for this study.